Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
VolitionRx Limited filings document an operating epigenetics diagnostics company with public-company disclosures centered on Nu.Q® assays, capital structure and exchange compliance. Recent 8-K reports and proxy materials cover shareholder votes on common-stock issuance capacity and reverse-stock-split authority, the effectiveness of a one-for-twenty reverse split, and amendments to the company’s certificate of incorporation.
The filing record also includes material-event reports on NYSE American continued-listing standards, annual financial-result updates, unregistered sales of equity securities, convertible-note share settlements, private placements and warrants. These documents describe governance approvals, security-holder rights, financing mechanics, listing-compliance matters and operating updates for Volition’s diagnostics and monitoring business.
VolitionRx (VNRX) filed an amended 8-K to replace Exhibit 1.1 and report an amendment to its underwriting agreement for a recent equity offering. The original deal covered 11,550,000 shares with accompanying warrants at a combined public price of $0.52 per share and warrant, less a 7.0% underwriting commission, and included a 30‑day over‑allotment option for up to 1,732,500 additional shares and accompanying warrants.
The amendment allows the underwriter to exercise the over‑allotment option for shares, warrants, or any combination, rather than only together. Concurrently, the underwriter exercised for 1,194,000 Option Shares and 1,732,500 Option Warrants at the same price terms. The filing states the 1,732,500 Option Warrants are exercisable for up to 83,580 shares. The amended exhibit corrects typographical errors and supersedes the prior version.
VolitionRx Limited amended its underwriting agreement for a recent public offering. The change lets the underwriter exercise the over-allotment option for shares, warrants, or any combination, rather than only as a combined unit.
On November 7, the underwriter exercised this option for 1,194,000 Option Shares and 1,732,500 Option Warrants at the same public pricing used in the offering, allocated as $0.51 per share and $0.01 per warrant, each less a 7.0% underwriting discount. The base offering previously covered 11,550,000 shares with accompanying warrants to purchase up to 11,550,000 shares at a combined public price of $0.52.
VolitionRx Ltd (VNRX) reported an insider tax-withholding transaction. On 11/01/2025, the Chief Medical Officer had 4,588 shares of common stock withheld (code F) at $0.434 per share to satisfy taxes upon settlement of 9,762 restricted stock units awarded in lieu of cash compensation. Following the transaction, the officer beneficially owns 146,568 shares, held directly. The filing notes that no shares were sold by the reporting person or the company in this transaction.
VolitionRx Ltd (VNRX) reported an insider Form 4 reflecting an administrative tax-withholding event. On 11/01/2025, the reporting officer (GC) had 5,647 shares of common stock withheld and canceled at $0.434 per share to satisfy taxes upon settlement of 12,016 restricted stock units awarded in lieu of cash compensation. The filing states no shares were sold by the insider or the company.
Following the transaction, the reporting person beneficially owned 194,084 shares, held directly.
VolitionRx Ltd. (VNRX) reported an insider transaction on a Form 4. On 11/01/2025, Officer and Secretary Rodney Gerard Rootsaert had 3,197 shares of common stock withheld by the company at $0.434 per share (transaction code F) to satisfy tax withholding upon settlement of 7,612 RSUs that were awarded in lieu of cash compensation. After the transaction, he beneficially owns 137,258 shares directly and 1,007,718 shares indirectly through Concord International, Inc. The filing states that no shares were sold in this transaction.
VolitionRx Ltd (VNRX) reported an insider tax-withholding event. On 11/01/2025, Salvatore Thomas Butera, CEO of Volition Veterinary, had 4,648 shares of common stock withheld and cancelled at $0.434 per share to satisfy taxes upon settlement of 16,996 restricted stock units awarded in lieu of cash compensation. The filing states no shares were sold by the insider or the company.
Following the transaction, Mr. Butera beneficially owned 321,803 shares directly, and 99,350 shares are jointly owned with his spouse.
VolitionRx Ltd (VNRX) reported an insider transaction by Chief Commercial Officer Gael Forterre. On 11/01/2025, 1,753 shares of common stock were withheld and cancelled by the company (Transaction Code F) at $0.434 per share to cover taxes upon settlement of 4,864 RSUs awarded in lieu of cash compensation. The filing states no shares were sold in this transaction.
Following the reported activity, Forterre beneficially owned 153,782 shares directly, plus 5,000 shares indirectly via spouse and 32,500 shares indirectly via Armorica Partners, LLC.
VolitionRx Ltd (VNRX) President & CEO Cameron John Reynolds, also a director, reported buying 110,000 common shares at $0.51 each and acquiring 110,000 warrants for $0.01 apiece, in connection with an underwritten public offering that closed on October 14, 2025.
The warrants are exercisable at $0.60 and expire on October 14, 2030. Following these transactions, he directly owns 2,534,847 common shares, with additional indirect holdings of 1,007,718 shares via Concord International, Inc. and 34,076 shares held by his spouse.
VolitionRx Ltd (VNRX) director Guy Archibald Innes purchased 96,153 shares of common stock on October 14, 2025 at $0.51 per share (the stock portion of a $0.52 unit price), and received warrants to buy 96,153 shares at an exercise price of $0.60 expiring October 14, 2030. The transaction occurred in connection with an underwritten public offering.
Following the transaction, he directly holds 1,062,967 common shares. Indirect positions are listed, including 1,400,000 shares by The Innes Family Bare Trust 2023 and 356,000 shares by The Dill Faulkes Educational Trust Limited, as disclosed. Additional indirect holdings include shares held for his children.
VolitionRx (VNRX) director reported buying 48,076 shares of common stock on October 14, 2025 in an underwritten public offering. The stock was acquired at $0.51 per share, and the purchase included warrants for 48,076 shares exercisable at $0.60 until October 14, 2030. The total unit price was $0.52, with $0.01 allocated to the warrant.
Following the transaction, the reporting person beneficially owned 1,535,458 shares directly.